Brodalumab API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Brodalumab API 1174395-19-7?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Brodalumab. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Brodalumab
- Synonyms:
- Cas Number:
- 1174395-19-7
- DrugBank number:
- DB11776
- Unique Ingredient Identifier:
- 6ZA31Y954Z
General Description:
Brodalumab, identified by CAS number 1174395-19-7, is a notable compound with significant therapeutic applications. Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
Indications:
This drug is primarily indicated for: Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Volume of Distribution:
Brodalumab is distributed throughout the body with a volume of distribution of: 4.62 L. This metric indicates how extensively the drug permeates into body tissues.
Clearance:
The clearance rate of Brodalumab is a critical factor in determining its safe and effective dosage: 0.223 L/day. It reflects the efficiency with which the drug is removed from the systemic circulation.
Pharmacodynamics:
Brodalumab exerts its therapeutic effects through: Increase in the level of IL-17 due to blocking of its receptors. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Brodalumab functions by: Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Brodalumab belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.
Categories:
Brodalumab is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Antibodies, Antibodies, Monoclonal, Antineoplastic and Immunomodulating Agents, Blood Proteins, Dermatologicals, Globulins, Immunoglobulins, Immunoproteins, Immunosuppressive Agents, Interleukin 17 Receptor A Antagonists, Interleukin Inhibitors, Interleukin-17 Receptor A Antagonist, Proteins, Receptors, Interleukin-17, Serum Globulins. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Brodalumab is a type of Anticancer drugs
Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.
Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.
These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.
Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.
